EMERYVILLE, CA, October 15, 2013, – KineMed, Inc. (www.kinemed.com) today announced an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.
KineMed’s biomarker platform will allow Amgen to track synthesis and clearance rates of pathogenic proteins in the brain that drive neurodegeneration.
“Normal brain aging and neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, are characterized by the accumulation of misfolded proteins in the brain. Diagnostic tests have not previously been available that reflect the underlying dynamics of the proteins believed to play a causal role in neurodegeneration. This has been a major obstacle in developing drugs that slow the accumulation of these misfolded proteins,” said Dr. Fanara, Vice President of Neuroscience at KineMed and Principal Investigator on this study.
Neurodegenerative disease is a significant health burden worldwide with few effective treatment options available to patients; according to the Harvard NeuroDiscovery Center, without the development of new treatments, in 30 years’ time more than 12 million Americans may be suffering from some form of neurodegenerative disease. The growing number of patients underscores the urgent need to build new tools to guide and accelerate the development of effective treatments for neurodegenerative disease.
About KineMed, Inc.
KineMed is a commercial-stage company with a biomarker platform technology that we believe is transformative for drug development, personalized medicine, and wellness monitoring. KineMed’s biomarker platform is designed to provide dynamic molecular information through a proprietary mass spectrometric platform that can be used to guide therapeutic decisions for individuals. We are developing prescription and non-prescription diagnostic tests for which we intend to seek FDA clearance for personalized medicine and the next generation of drug development. We intend to generate revenue though these programs from patients, payors, drug developers, and through corporate partnerships.
KineMed’s systems biology technology is designed to be used directly in humans, with applications not only in drug discovery and development, but also in clinical diagnosis, personalized medicine and therapeutic monitoring, including over the counter wellness decisions. We are developing three programs based on our proprietary technology:
Drug discovery and development. We enter into co-development agreements with pharmaceutical and biotechnology companies to improve the efficiency of drug development.
Prescription and non-prescription diagnostic tests. We are developing diagnostic tests for which we intend to seek FDA clearance that are designed to provide personalized information about key biologic processes to allow precision medical management based on disease subtype and activity and to enable informed wellness decisions.
KineMed’s platform applies to diagnosis and management across the spectrum of diseases, including conditions involving fibrosis, neurodegeneration, muscle loss, metabolic cardiovascular or dermatologic disorders and cancer, as well as consumer wellness.
Diagnostic test/drug pairings. We intend to pair diagnostic tests with therapeutic agents to develop in-house drug candidates and invigorate underperforming drugs and nutraceuticals.
Over the past few years, KineMed has influenced academic literature about diseases and the development path of several drug candidates. Notable accomplishments include:
Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)
Developing the first blood-based biomarker of tissue fibrogenesis in humans known to us
Generating the first non-invasive laboratory biomarkers of muscle mass and muscle quality in humans known to us
Creating the first diagnostic tests of disease-modifying processes known to us in a neurodegenerative disease (Parkinson’s disease)
Developing a “tachometer” of reverse cholesterol transport and metrics of plasma lipid dynamics
Identifying new, secondary indications for drug candidates in pharmaceutical pipelines
Identifying new targets for drug development in several important diseases
Ravi Kiron, Ph.D., MBA, Chief Business Officer
Tel: 510-655-6525 ext. 105